INTRODUCTION: Several studies have demonstrated dysbiosis in irritable bowel syndrome (IBS). Therefore, faecal microbiota transplantation, whose effect and safety have been proven in Clostridioides difficile infections, may hold promise in other conditions, including IBS. Our study will examine the effectiveness of stool transfer with artificially increased microbial diversity in IBS treatment. METHODS AND ANALYSIS: A three-group, double-blind,randomised, cross-over, placebo-controlled study of two pairs of gut microbiota transfer will be conducted in 99 patients with diarrhoeal or mixed type of IBS. Patients aged 18-65 will be randomised into three equally sized groups: group A will first receive two enemas of study microbiota mixture (deep-frozen stored stool microbiota mixed from eight healthy donors); after 8 weeks, they will receive two enemas with placebo (autoclaved microbiota mixture), whereas group B will first receive placebo, then microbiota mixture. Finally, group C will receive placebos only. The IBS Severity Symptom Score (IBS-SSS) questionnaires will be collected at baseline and then at weeks 3, 5, 8, 11, 13, 32. Faecal bacteriome will be profiled before and regularly after interventions using 16S rDNA next-generation sequencing. Food records, dietary questionnaires, anthropometry, bioimpedance, biochemistry and haematology workup will be obtained at study visits during the follow-up period. The primary outcome is the change in the IBS-SSS between the baseline and 4 weeks after the intervention for each patient compared with placebo. Secondary outcomes are IBS-SSS at 2 weeks after the intervention and 32 weeks compared with placebo and changes in the number of loose stools, Bristol stool scale, abdominal pain and bloating, anthropometric parameters, psychological evaluation and the gut microbiome composition. ETHICS AND DISSEMINATION: The study was approved by the Ethics Committee of Thomayer University Hospital, Czechia (G-18-26); study results will be published in peer-reviewed journals and presented at international conferences and patient group meetings. TRIAL REGISTRATION NUMBER: NCT04899869.

Department of Internal Medicine Charles University 3rd Faculty of Medicine Prague Czech Republic

Department of Medical Microbiology Charles University 2nd Faculty of Medicine Prague Czech Republic

Department of Paediatrics Charles University 2nd Faculty of Medicine Prague Czech Republic

Department of Probability and Statistics Charles University Prague Czech Republic

See more in PubMed

Lacy BE, Mearin F, Chang L, et al. . Bowel disorders. Gastroenterology 2016;150:1393–407. 10.1053/j.gastro.2016.02.031 PubMed DOI

Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712–21. 10.1016/j.cgh.2012.02.029 PubMed DOI

Rajilić-Stojanović M, Jonkers DM, Salonen A, et al. . Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 2015;110:278–87. 10.1038/ajg.2014.427 PubMed DOI PMC

Kelly CP. Fecal microbiota transplantation--an old therapy comes of age. N Engl J Med 2013;368:474–5. 10.1056/NEJMe1214816 PubMed DOI

Johnsen PH, Hilpüsch F, Cavanagh JP, et al. . Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018;3:17–24. 10.1016/S2468-1253(17)30338-2 PubMed DOI

El-Salhy M, Hatlebakk JG, Gilja OH, et al. . Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut 2020;69:859–67. 10.1136/gutjnl-2019-319630 PubMed DOI PMC

Halkjær SI, Christensen AH, Lo BZS, et al. . Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut 2018;67:2107–15. 10.1136/gutjnl-2018-316434 PubMed DOI

Aroniadis OC, Brandt LJ, Oneto C, et al. . Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol 2019;4:675–85. 10.1016/S2468-1253(19)30198-0 PubMed DOI

Holster S, Lindqvist CM, Repsilber D, et al. . The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study. Clin Transl Gastroenterol 2019;10:e00034. 10.14309/ctg.0000000000000034 PubMed DOI PMC

Lahtinen P, Jalanka J, Hartikainen A, et al. . Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther 2020;51:1321–31. 10.1111/apt.15740 PubMed DOI

Holvoet T, Joossens M, Vázquez-Castellanos JF, et al. . Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology 2021;160:145–57. 10.1053/j.gastro.2020.07.013 PubMed DOI

Wu J, Lv L, Wang C. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Front Cell Infect Microbiol 2022;12:827395. 10.3389/fcimb.2022.827395 PubMed DOI PMC

Chan A-W, Tetzlaff JM, Altman DG, et al. . Spirit 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583 PubMed DOI PMC

Cammarota G, Ianiro G, Kelly CR, et al. . International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut 2019;68:2111–21. 10.1136/gutjnl-2019-319548 PubMed DOI PMC

Nanjing consensus on methodology of washed microbiota transplantation. Chin Med J 2020;133:2330–2. 10.1097/CM9.0000000000000954 PubMed DOI PMC

Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395–402. 10.1046/j.1365-2036.1997.142318000.x PubMed DOI

Kozich JJ, Westcott SL, Baxter NT, et al. . Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 2013;79:5112–20. 10.1128/AEM.01043-13 PubMed DOI PMC

Callahan BJ, McMurdie PJ, Rosen MJ, et al. . DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods 2016;13:581–3. 10.1038/nmeth.3869 PubMed DOI PMC

Kramná L, Cinek O. Virome sequencing of stool samples. Methods Mol Biol 2018;1838:59–83. 10.1007/978-1-4939-8682-8_6 PubMed DOI

Palsson OS, Baggish JS, Turner MJ, et al. . Ibs patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol 2012;107:286–95. 10.1038/ajg.2011.358 PubMed DOI PMC

Stensvold CR, van der Giezen M. Associations between gut microbiota and common luminal intestinal parasites. Trends Parasitol 2018;34:369–77. 10.1016/j.pt.2018.02.004 PubMed DOI

Hurych J, Vodolanova L, Vejmelka J, et al. . Freezing of faeces dramatically decreases the viability of Blastocystis sp. and Dientamoeba fragilis. Eur J Gastroenterol Hepatol 2022;34:242–3. 10.1097/MEG.0000000000002327 PubMed DOI

Faecal Bacteriome and Metabolome Profiles Associated with Decreased Mucosal Inflammatory Activity Upon Anti-TNF Therapy in Paediatric Crohn's Disease

See more in PubMed

ClinicalTrials.gov
NCT04899869